J&J: encouraging results for Xarelto in PAD

(CercleFinance.com) - Johnson & Johnson's (J&J) Janssen Pharmaceutical Companies had presented a new analysis relating to a phase III trial highlighting the benefits of Xarelto (rivaroxaban) (2.
5 mg twice daily plus aspirin 100 mg once daily) compared with the standard of care dose (aspirin alone).

The benefit of Xarelto + aspirin was consistent at 30 days, 90 days, and up to three years after lower extremity revascularization in patients with peripheral artery disease (PAD).

Xarelto plus aspirin resulted in a 33% reduction in acute limb ischemia and a 15% reduction in major adverse limb and cardiovascular events, with or without dual antiplatelet therapy (DAPT).

This latest XARELTO data was presented at the American College of Cardiology's 72nd Annual Scientific Session (ACC.23), held in New Orleans, Louisiana, on 4 to 6 March.


Copyright (c) 2023 CercleFinance.com. All rights reserved.